Acalabrutinib plus R-miniCHOP for untreated lymphoma in older adults
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether adding acalabrutinib to a reduced-strength chemotherapy plan (R-miniCHOP) works better and is safer for older adults with newly diagnosed diffuse large B-cell lymphoma. It may help you get a more effective treatment while using a dosing approach meant for people who may not tolerate full-strength therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign the consent form (and follow its rules).
- You must be able to swallow study tablets/capsules without difficulty.
- You are age 61–80 and not eligible for full-dose R-CHOP, or you are over 80.
- Your lymphoma is confirmed as CD20-positive diffuse large B-cell lymphoma, diagnosed for the first time.
- Your general strength is limited but still workable (ECOG score 0–2; score 3 only if caused by lymphoma).
- Your bloodwork and organ function meet minimum thresholds (including kidneys and liver).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
This Phase 2 trial studies whether adding acalabrutinib to intensive chemo (DA-EPOCH-R or R-CHOP) works better for people newly diagnosed with aggressive diffuse large B-cell lymphoma (DLBCL) or related high-grade B-cell lymphomas. It may help shrink cancer and control the disease by targeting lymphoma in two different ways.
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
This trial tests a new targeted therapy (AZD0486) as a first treatment for older or less fit people with large B-cell lymphoma. It is for those who cannot tolerate the usual strong chemo, aiming to be gentler while still fighting the cancer.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.